Acute leukemias are uncontrolled expansions of immature hematopoietic cells. If untreated, these diseases are rapidly fatal. Acute leukemias destroy the ability of the bone marrow to produce the neutrophils and platelets required respectively to defend against bacterial infection and to maintain the integrity of the vascular system. Death usually results from infection or bleeding. Cytotoxic chemotherapy and improvements in supportive care have prolonged survival for patients with acute leukemia. Nevertheless, cytotoxic agents have severe side-eects, including a risk of secondary malignancies, and survival of patients with acute leukemias of non-lymphoid cells has remained poor. The creation of mouse models that re¯ect the genetic underpinnings of human leukemias oers the prospect that advances in knowledge of pathogenesis will be translated into improved therapies.
Leukemogenesis
Our understanding of the molecular mechanisms that transform normal cells into malignant cells has grown enormously in the past two decades. Progress in understanding normal hematopoiesis and leukemia has been particularly rapid. In normal hematopoiesis, stem cells give rise to lineage restricted progenitors that in turn can dierentiate into mature cells. Immature progenitors respond to environmental cues that stimulate production of mature cells while maintaining a balance among self-renewal, cell death, and dierentiation ( Figure 1a) . Many of the proteins that control these varied processes have been identi®ed. In acute leukemia, cells have acquired genetic alterations that inhibit dierentiation and may make the cells resistant to environmental cues (Figure 1b) . Alterations in transcription factors contribute to dierentiation arrest in many acute leukemias but the combinations of genetic changes required for human leukemogenesis have not yet been de®ned. While traditional leukemia therapy relies upon killing the malignant cells, the future of therapy lies in abrogating the eects of pathogenic genetic abnormalities. Such therapies could reverse the arrest of dierentiation or re-establish responsiveness to signals that limit cell growth.
Dierentiation therapy of acute promyelocytic leukemia
The best described example of a cancer treatment that restores normal behavior to malignant cells is the use of all-trans retinoic acid (tRA) to treat a sub-type of acute non-lymphocytic leukemia (ANLL), acute promyelocytic leukemia (APL). In this review, we summarize the remarkable story of how a novel therapy sped the discovery of molecular lesions that underlie APL. In addition, we explore how animal models of APL can be used to study pathogenesis, elucidate eects of tRA, and improve therapy.
APL accounts for approximately 10% of ANLL (Stone and Mayer, 1990) . The disease results from the uncontrolled expansion of cells at the promyelocyte stage of neutrophilic dierentiation. In humans, APL is characterized by abnormal promyelocytes including cells with multiple rod-shaped primary granules (Auer rods), peripheral white blood cell counts that are commonly normal or even low, and abnormal blood coagulation. In 1977 a reciprocal chromosomal translocation of chromosomes 15 and 17, t(15;17)(q22;q21), was identi®ed to be tightly associated with APL (Rowley et al., 1977) , but until 1990 the genes aected by the translocation were not known.
In 1987, a group from Shanghai, China, made the astounding discovery that tRA could induce clinical remissions in patients with APL (Huang et al., 1987) . The role of retinoids in development and dierentiation had led to the idea that these molecules might be useful in the treatment of human leukemias and solid tumors (Smith et al., 1992; Sporn et al., 1994) . Among ANLLS, APL had been observed to be particularly sensitive to the dierentiative eects of retinoic acid (Breitman et al., 1981) . Huang et al. (1988) showed that tRA induced clinical remission in APL by stimulating the dierentiation of the leukemic promyelocytes. Although tRA was not curative and resistance rapidly developed, in combination with cytotoxic chemotherapy tRA dramatically improved survival .
Chromosomal breakpoints in APL
In 1988, the gene encoding a retinoic acid receptor, RARa, was mapped to the q21 band of chromosome 17, near the breakpoint of the APL-associated t(15;17)(q22;q21) translocation (Mattei et al., 1988) .
In light of the preceding observation that APL cells dierentiated in response to tRA, a number of investigators evaluated the hypothesis that the t(15;17) translocation altered the RARa gene (Warrell et al., 1993) . The breakpoint on chromosome 17 was in fact identi®ed within RARa Borrow et al., 1990; de The et al., 1990) , while the breakpoint on chromosome 15 was identi®ed within a previously unknown gene given the name PML (de Goddard et al., 1991; Kakizuka et al., 1991; Kastner et al., 1992; Pandol® et al., 1991) . The common t(15;17) translocation creates PMLRARa and RARaPML fusion genes. Rare cases of APL contain chromosomal rearrangements that fuse RARa with other partners: PLZF in t(11;17)(q23;q21) (Chen Z et al., 1993) , NPM in t(5;17)(q32;q21) (Redner et al., 1996) , and NuMA in t(11;17)(q13;q21) (Wells et al., 1997) . Following the identi®cation of the RARa fusion genes associated with APL, eorts have been directed towards elucidating how these abnormal genes contribute to APL pathogenesis and to tRA responsiveness.
Experimental approaches
A number of experimental approaches to the study of APL have been developed. The NB4 cell line derived from an APL patient has served as a model of APL both in tissue culture and as a xenograft in mice (Lanotte et al., 1991; Zhang et al., 1996b) . The transduction of other cell lines with PMLRARa and related variants has also been a productive approach (Grignani et al., 1993 (Grignani et al., , 1995 Rousselot et al., 1994; Testa et al., 1998) . Cell lines nevertheless have limitations, which are particularly apparent in attempts to elucidate how genetic changes alter the behavior of normal cells and combine to confer a malignant phenotype, and in assessing therapies in a biological context analogous to human illness. For these reasons, mouse models of APL are a desirable tool. We and others expressed a human PMLRARa cDNA as a transgene in the neutrophilic cells of mice and thereby created mouse models of APL (Brown et al., 1997; Grisolano et al., 1997; He et al., 1997) . These models are discussed in additional current review articles (He et al, 1999; Westervelt and Ley, 1999) .
The MRP8-PMLRARa model of APL Our laboratory generated a model of APL by expressing PMLRARa under the control of the MRP8 promoter (Brown et al., 1997) . MRP8 is a small calcium binding protein expressed in myeloid cells including neutrophils and monocytes (Lagasse and Weissman, 1992) . In MRP8-PMLRARa transgenic mice, PMLRARa expression caused abnormal differentiation of neutrophilic cells and some of the mice developed acute leukemia.
The leukemias initiated by the MRP8-PMLRARa transgene had features in common with human APL, including bone marrow eaced by cells at the promyelocyte stage of neutrophilic dierentiation and lack of increased white blood cell counts. Similar to many transgenic models of malignancy, we observed a correlation between transgene expression and penetrance of the leukemia: whereas leukemias were rare in transgenic lines with low level expression, greater than 50% of mice of our highest expressing line developed leukemia by the age of 18 months. Our model of APL, as well as those generated by others, demonstrated that the PMLRARa fusion protein has a causal role in APL.
Model validation
It is important to characterize mouse models of malignancy in order to validate the extent to which they recapitulate features of human neoplasms. In addition to the APL-like morphologic features described above, we have demonstrated that the disease arising in our MRP8-PMLRARa transgenic mice meets a biologic de®nition of acute leukemia: it is a rapidly progressive illness that disseminates widely and is readily transplantable into immunocompetent histocompatible mice. As in humans, the leukemias show a dramatic response to tRA. In most cases, there is a sharp rise in the peripheral white blood cell count as the leukemic promyelocytes dierentiate to mature neutrophils. In the bone marrow tRA induces morphologic remission. As is also seen in human patients, tRA prolongs the life of the leukemic mice but is not curative. Thus, this murine model is suitable for studies of both pathogenesis and response to therapy.
The model does not, however, completely recapitulate the human illness. We have not observed the Auer rods characteristic of human APL in our mice. In addition, the possibility that the model might be useful for studies of the APL-associated coagulation disorder has to date not been con®rmed. The fact that there are both similarities and dierences between the MRP8-PMLRARa model and human APL illustrates the importance of de®ning the areas of investigation for which a particular model will be useful.
Pathogenesis of APL, the role of PMLRARa
The PMLRARa fusion protein may contribute to leukemic transformation by aecting the normal activities of the RARa protein, the PML protein, and/or additional factors. RARa is a ligand-inducible transcription factor (Mangelsdorf and Evans, 1995) . In the absence of tRA, RARa recruits co-repressor molecules including SMRT and N-CoR, which in turn recruit histone deacetylases leading to transcriptional repression. In the presence of tRA, co-repressors are released and co-activators are recruited resulting in gene expression. Depending on cell type and promoter examined, PMLRARa can increase or decrease basal levels of transcription from retinoic acid response elements (RAREs). In response to the tRA ligand, PMLRARa can act as a superactivator or as a dominant negative inhibitor (de The et al., 1991; Kakizuka et al., 1991; Kastner et al., 1992; Pandol® et al., 1991; Rousselot et al., 1994; Ruthardt et al., 1997) . It has been unclear whether the pathogenic role of PMLRARa rests in its ability to act as a transcriptional activator, a transcriptional repressor with a dominant negative activity, or both.
To assess the importance of transcriptional activation and repression in leukemogenesis, we expressed variant PMLRARa and RARa proteins in transgenic mice (Kogan et al., 1999) . For this purpose, we utilized a leucine to proline mutation at amino acid 398 of RARa that markedly impairs the ability of PMLRARa and RARa to bind and respond to retinoic acid (Shao et al., 1997) . This m4 mutation converts PMLRARa and RARa from ligand-responsive transcription factors into constitutive repressors with dominant negative activity. The mutated form of PMLRARa, PMLRARam4, readily initiated leukemias that were similar to leukemias in our original PMLRARa transgenic mice. Since PMLRARam4 does not respond to ligand, this result demonstrated that ligand-induced transcriptional activation is not required for PMLRARa to initiate leukemia. In contrast, RARam4 expression did not signi®cantly impair neutrophilic dierentiation and did not initiate leukemia. Since RARam4 exhibits dominant negative activity, this result provided evidence that PMLRARa is not simply a dominant negative RAR and that the PML domain plays an essential role in PMLRARa-mediated leukemogenesis.
Our results ®t into an emerging understanding of the mechanisms by which PMLRARa contributes to leukemia (Figure 2 ). Two lines of evidence indicate that the ability of PMLRARa to initiate leukemia depends on its ability to repress transcription. First, PMLRARa expression in the U937 promonocytic cell line blocked dierentiation of these cells in response to vitamin D3 and TGFb (Grignani et al., 1993) but a form of PMLRARa impaired in co-repressor binding was unable to block dierentiation . Second, a rare subset of APL patients harbor a t(11;17)(q23;q21) chromosomal translocation and express the resultant PLZFRARa fusion gene (Chen et al., 1993b) . In these patients, tRA does not induce clinical remission (Chen et al., 1993a; Licht et al., 1995) . The fact that tRA induces remissions of leukemias that express PMLRARa but not those that express PLZFRARa correlates with the ability of pharmacologic doses of tRA to release co-repressors from PMLRARa but not from PLZFRARa Guidez et al., 1998; He et al., 1998; Hong et al., 1997; Lin et al., 1998) . This correlation implies that abnormal repression is important for leukemogenesis.
The genes whose repression by PMLRARa contributes to leukemia have not yet been identi®ed. One hypothesis is that PMLRARa inhibits dierentiation by interfering with the expression of genes normally regulated by retinoic acid receptors (Grignani et al., 1993; Rousselot et al., 1994) . In support of this hypothesis is the observation that retinoic acid can enhance neutrophilic dierentiation (Douer and Koefer, 1982; Gratas et al., 1993) . However, the absence of leukemia in mice expressing a dominant negative form of RARa suggests that abnormal repression at RAREs is not sucient for leukemia initiation (Kogan et al., submitted). Furthermore, retinoids may have only a minor physiologic role in neutrophilic dierentiation: mice that lack RARa1 and RARg (which comprise the vast majority of RARs expressed in myeloid cells) have no apparent hematopoietic defect in vivo and neutrophilic cells from these mice display only a modest maturation defect in vitro (Labrecque et al., 1998) .
PMLRARa may block dierentiation by interfering with transcription of genes regulated by non-RAR factors. For example, RARs normally function as heterodimers with the related nuclear hormone receptors, RXRs. RXRs are partners for several non-RAR nuclear hormone receptors and PMLRARa can alter transcription normally mediated by these other receptors (Perez et al., 1993) . PMLRARa can also in¯uence transcription at AP-1 elements (Doucas et al., 1993) . In addition, compared to RARa, PMLRARa has an altered anity for various binding sites and therefore has a unique impact on gene expression Figure 2 PMLRARa in leukemogenesis and in retinoic acid response. PML limits proliferation and survival of promyelocytes, possibly through activities exerted within nuclear bodies. PML may also enhance myeloid dierentiation (Wang et al., 1998a) . Normal transcription factors including RARa regulate neutrophil maturation. PMLRARa inhibits dierentiation, decreases cell death, and increases proliferation by interfering with PML function and by repressing transcription of as yet unidenti®ed genes. It appears that other genetic changes are necessary to complete the process of malignant transformation. In the presence of pharmacologic levels of retinoic acid, PMLRARa activates transcription of genes necessary for neutrophilic maturation (Perez et al., 1993; Jansen et al., 1995) . At this time, the speci®c transcriptional eects of PMLRARa that are pathogenic remain elusive.
In addition to altering transcription, PMLRARa can disrupt the normal function of PML. PML is a component of nuclear bodies (NBs) that are composed of multiple proteins and are associated with the nuclear matrix (Hodges et al., 1998; Lamond and Earnshaw, 1998) . While the function of these NBs remains uncertain, a number of lines of evidence implicate PML as a regulator of proliferation and survival: PML is able to suppress cell growth (Borden et al., 1997; Koken et al., 1995; Le et al., 1998; Mu et al., 1994) and loss of PML predisposes mice to a variety of tumors (Wang et al., 1998a) ; cells lacking PML grow more quickly than normal cells and are resistant to apoptosis induced by a variety of agents (Wang et al., 1998a,c) ; and PMLRARa can disrupt the structure of NBs (Daniel et al., 1993; Dyck et al., 1994; Koken et al., 1994; Weis et al., 1994) and can block the ability of PML to induce apoptosis (Grignani et al., 1993; Wang et al., 1998c) . It is therefore likely that disruption of PML function by PMLRARa contributes to APL pathogenesis.
Pathogenesis of APL, the role of other events
PMLRARa clearly plays a causal role in the development of APL. However, the eects of PMLRARa on PML and on transcription do not appear sucient to confer a fully malignant phenotype on murine promyelocytes (Brown et al., 1997; Grisolano et al., 1997; He et al., 1997) . Therefore, other genetic changes are required for APL. Mouse models of this leukemia should facilitate the identification of these cooperating events.
The t(15;17) translocation results not only in the production of a PMLRARa fusion gene, it also creates the reciprocal RARaPML fusion and causes haploinsuciency for PML and RARa. Emerging data indicate that expression of RARaPML and loss of Pml increase the penetrance of leukemia in transgenic mice expressing PMLRARa, but these combinations do not cause neonatal acute leukemia (Pollock et al., 1997; Wang et al., 1998b) . Thus, single-step leukemogenesis for APL remains a speculative idea. An alternative hypothesis is that the genetic changes conferred by the t(15;17) translocation disrupt the normal balance among self-renewal, survival, and terminal maturation of promyelocytes, but that additional changes must occur for leukemia to develop. According to such a hypothesis, full transformation depends not only on imbalance of internal pathways that regulate cell fate but also on release from external regulatory signals. Such regulatory signals include cytokines within the bone marrow milieu that regulate the number and types of hematopoietic cells produced. The ability of promyelocytes to survive and undergo self-renewal may normally be limited by cues speci®c to a bone marrow microenvironment. We speculate that abnormalities in growth factor production or signaling might free cells from external growth controls and cooperate with the t(15;17) translocation to induce leukemia. The APL mouse models provide the means to test this hypothesis.
Mechanism of action of tRA
Retinoic acid induces remissions in APL by causing the malignant promyelocytes to dierentiate. The effectiveness of tRA therapy could be due to direct eects upon the PMLRARa protein and/or to eects mediated through normal retinoic acid binding proteins. There is now strong evidence that direct eects upon PMLRARa are central to the tRA response of APL: not only have mutations in the ligand-binding domain of PMLRARa been associated with retinoic acid resistance in APL cell lines and patient samples (Ding et al., 1998; Imaizumi et al., 1998; Kitamura et al., 1997; Shao et al., 1997) , the leukemias that arose in transgenic mice expressing a ligand-nonresponsive form of PMLRARa did not dierentiate in response to tRA (Kogan et al., submitted) .
Ligand binding to PMLRARa induces multiple eects, including degradation of the fusion protein, release of transcriptional repression, and stimulation of transcriptional activation. Which of these eects is important for tRA responsiveness has been an area of some controversy. Degradation of the fusion protein has been suggested to contribute to dierentiation (Raelson et al., 1996; Yoshida et al., 1996) . However, tRA induced dierentiation of PMLRARa-expressing cells even when protein degradation was blocked . In contrast, release of repression is clearly important in tRA response: as discussed above, clinical tRA responsiveness correlates with the ability of PMLRARa and PLZFRARa to release corepressors; and histone deacetylase inhibitors, which abrogate co-repression, synergized with tRA to induce dierentiation Guidez et al., 1998; He et al., 1998; Lin et al., 1998) . Nevertheless, diverse evidence has also implicated ligand-induced transactivation by PMLRARa in the unique sensitivity of APL cells to tRA. First, release of repression was not sucient to cause dierentiation of APL cells: in the absence of tRA, histone deacetylase inhibitors had dierentiative eects that ranged from absent to modest Guidez et al., 1998; He et al., 1998; Lin et al., 1998) . Second, ribozymemediated inhibition of PMLRARa expression in NB4 cells caused growth suppression and apoptosis without dierentiation (Nason-Burchenal et al., 1998) . Third, expression of PMLRARa in U937 cells enhanced the ability of tRA to both activate transcription of retinoic acid responsive genes and stimulate dierentiation (Grignani et al., 1993; Ruthardt et al., 1997) and, moreover, a form of PMLRARa able to activate transcription but unable to bind co-repressors similarly facilitated dierentiation .
The eects of tRA may extend beyond its ability to cause activation of transcription by PMLRARa. A clinical response to tRA has been observed for leukemias expressing fusion proteins that are insensitive to retinoic acid: retinoic acid prolonged survival of leukemic mice expressing the PLZFRARa fusion protein (He et al., 1998) , and we observed that tRA prolonged survival of some mice with PMLRARam4 leukemias without causing morphologic dierentiation (Kogan et al., submitted) . These surprising results suggest that tRA may, in combination with other agents, be therapeutically useful even in patients with APL that is resistant to tRA-induced dierentiation.
Pre-clinical studies
The development of new treatments for cancer has relied traditionally upon in vitro studies and xenograft models followed by human clinical trials. The lack of animal models re¯ective of human cancer biology made the transition from animal testing to human treatment a dicult leap. Furthermore, the absence of animal models re¯ective of the genetic alterations that occur in human cancer severely limited the ability to test therapies designed to reverse the eects of pathogenic mutations. Murine models speci®cally developed to re¯ect the genetics and biology of human cancers should aid the development of novel therapies by narrowing the gap between animal and human testing.
Key features of a particular murine model in¯uence how powerful a tool it is for evaluating therapies. Low penetrance and long latency may make a model impractical for pre-clinical studies. Excessive variability in disease phenotype may make interpretation of studies dicult, whereas some degree of variation is useful in re¯ecting disease heterogeneity in humans.
Our experience with murine APL illustrates how a model's characteristic shape its use. The leukemias that arise in MRP8-PMLRARa mice develop after three months of age and accumulate slowly within the population. In individual mice, the interval between clinically apparent leukemia and death is only a few days. Evaluating therapy in such a system would require large numbers of mice and could take months (or years). Fortunately, the transplantation of leukemic cells into histocompatible normal mice reproduced the behavior of leukemias arising in previously healthy animals. Transplantability has enhanced the value of our model for pre-clinical studies. Leukemic cells can be cryopreserved and made widely available. Large numbers of leukemic animals can be generated without the need to maintain a large mouse colony. The transplantable nature of the disease allows for consistency in analysis, because multiple animals engrafted with the same leukemic cells develop leukemia contemporaneously. Further, variability among dierent leukemias can be readily assessed because multiple independently derived leukemias can be studied.
The MRP8-PMLRARam4 model has recently been utilized to investigate a novel therapeutic approach for APL (Lallemand-Breitenbach et al., 1999) . The treatment regimen studied did not rely upon standard cytotoxic chemotherapy but instead combined tRA with arsenic trioxide (arsenic). Traditional Chinese medicines that contain arsenic had been observed to be eective therapy for APL patients (Sun et al., 1992) . The anti-leukemia activity of arsenic itself was subsequently reported and arsenic was observed to induce remissions in patients with tRA-resistant disease (Shen et al., 1997; Soignet et al., 1998; Zhang et al., 1996a) . The anti-leukemic eect of arsenic appears to lie primarily in induction of apoptosis and secondarily in enhancing dierentiation (Chen et al., 1996 Kizaki et al., 1998; Soignet et al., 1998) . In order to examine the possible use of arsenic in combination with tRA, cohorts of immunocompetent mice engrafted with APL cells were treated with placebo, tRA, arsenic, or both (Lallemand-Breitenbach et al., 1999) . Arsenic induced apoptosis, promoted dierentiation, and prolonged survival. Combination therapy with arsenic and tRA led to enhanced dierentiation and apoptosis, rapid regression of disease, and apparent eradication of the leukemic cells. These results indicate that combining tRA and arsenic therapy might be useful as an initial regimen for human APL patients.
APL as a paradigm for gene-directed therapy
The discovery that retinoic acid was an eective therapy for APL preceded the ®nding that a molecular abnormality of a retinoic acid receptor underlies APL pathogenesis. Nevertheless, tRA therapy of APL is a paradigm for gene-directed therapy which speci®cally targets pathogenic genetic abnormalities. Retinoic acid has greatly improved long term survival for one subtype of one malignancy. The community of scientists and clinicians dedicated to caring for patients with cancer are faced with the challenge of utilizing our knowledge of pathogenesis to develop gene-directed therapies for other malignancies. The example of tRA therapy in APL presents the hope that these eorts can lead to dramatically improved survival in other types of leukemias and in solid tumors. Murine models can be expected to have an important place in these eorts.
